The Digital Medicine Society (DiME) launched a new set of FDA-aligned digital measures to standardize how outcomes are tracked in pediatric rare disease trials. The framework aims to make trials faster and more efficient, giving researchers and drugmakers a practical roadmap for developing new therapies for children who often have no effective treatment options.
The post How DiME’s New Pediatric Rare Disease Project Could Make Clinical Trials Faster appeared first on MedCity News.
